☰

Edocera Sp. z o.o.

Carrying a wearable stroke monitor from prototype to clinical evidence

Industry
Medical Devices — Wearable Stroke Detection
Headquarters
Warsaw, Poland
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Edocera Sp. z o.o.'s published strategy and is not endorsed by, or produced in cooperation with, Edocera Sp. z o.o.. Company website

Strategic priorities

Edocera Sp. z o.o. is a Special Purpose Vehicle inside the Scope Fluidics S.A. group, an entity listed on the Warsaw Stock Exchange. As of late 2025 the project had moved from technology verification into active R&D for a prototype wearable, and is one of three SPVs the group runs in parallel alongside Bacteromic Sp. z o.o. and Hybolic Sp. z o.o. The group's stated funding need for 2025 to 2027 is approximately PLN 240 million, with cash on hand above PLN 110 million at the end of Q3 2025 and a Series K private placement of more than PLN 64 million executed in October 2025.

The product proposition is continuous wearable monitoring with AI-assisted detection of pre-stroke signals. Public documentation describes a device that combines monitoring hardware with software that 'continuously tracks a patient's vital health parameters' and 'detects critical changes' using 'sophisticated algorithms.' As a connected medical wearable with AI-driven diagnostics, the product sits inside both EU IVDR and US FDA scrutiny, and the group has confirmed it is expanding cooperation with FDA certification advisors following the Bacteromic IVDR dossier submission in late 2025.

Manufacturing for the group's cartridge and sensor products is in the process of moving from pilot to scale at a site near Warsaw operated by Technicolor Precision BioDevices. The Piaseczno facility carries a dedicated manufacturing line for the group's diagnostic components and is the test bed for semi-automated, industrial-scale production. The agreement is designed to transition from pilot to large-scale cartridge manufacturing over the contract window.

The exit pattern the group has already proven sets the destination. Curiosity Diagnostics was sold to Bio-Rad Laboratories for a total transaction value of around USD 130 million, with the final USD 30 million conditional settlement reported in 2025. The next transaction is expected to follow the same template, which makes the data, manufacturing and regulatory history behind Edocera part of the negotiating surface as much as the patents themselves.

Challenges we see

  • Operations Manufacturing

    Moving from creative prototyping to repeatable industrial production

    Edocera has completed technology verification and begun R&D on prototype devices. The shift from a creative prototyping environment to a disciplined, repeatable industrial line is the immediate operational focus.

    Where prototyping is conducted by small teams with custom workflows, the move to industrial production is made easier when the same workflow can be replayed across teams and machines without each iteration needing to be re-learned.

  • Operations Integration

    Coordinating a multi-tier component supply chain

    Wearable sensor systems integrate micro-sensors, flexible electronics and battery subsystems across specialised suppliers and the Technicolor manufacturing partnership. The group's Bacteromic project has already triggered a one-year manufacturing agreement for pilot and scale production.

    Where components and assemblies move between several suppliers, a single view of part status, lot history and qualification evidence is what lets a release decision be made from one place rather than reconstructed from several.

  • Digital Integration

    Processing high-frequency wearable telemetry without clinical-grade latency

    Continuous stroke monitoring requires near-real-time processing of telemetry from many wearable devices. Public materials describe the product as 'real-time stroke prevention and diagnosis,' and the algorithms as capable of detecting 'critical changes.'

    Where the value of the product depends on a clinician being notified in seconds rather than minutes, the cloud architecture is part of the clinical claim, not separate from it.

  • Compliance Regulatory

    Compiling IVDR and FDA evidence from fragmented sources

    Bacteromic submitted its full IVDR dossier in late 2025 with an International Clinical Advisory Board. Edocera will follow the same pathway alongside FDA certification work. The work combines clinical evidence, manufacturing validation and cybersecurity documentation across two regulatory regimes.

    Where dossier evidence lives in lab notebooks, manufacturing records and design documents, the dossier itself is faster to assemble when the source records can be queried together rather than collected by hand.

  • Digital Operations

    Connecting product design and manufacturing data across sites

    The group runs R&D in Warsaw and manufacturing near Warsaw at the Piaseczno site, with FDA and clinical activity in the United States. Manufacturing and design data are typically held in separate systems.

    Where the device's hardware and software are inseparable in the field, traceability from a manufactured lot back to the design and software version that produced it is built by joining the two estates rather than by reconciling them later.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Screening discovery-stage initiatives with shared evidence

    Scope Discovery ran 63 initiatives in the pipeline as of Q3 2025. Manual screening, tracking and evaluation of that volume is the bottleneck between discovery and a new SPV.

    A shared data layer for discovery work, with initiative screening drawn from the same evidence the team reads, lets each new project pick up what earlier projects recorded rather than restarting the assessment.

    • Scope Fluidics Q1-Q3 2025 results, 2025
    • Scope Fluidics after Q1 2025: Focus on Project Development

  2. Linking Piaseczno production data to Scope Fluidics quality requirements

    The Piaseczno manufacturing site, operated with Technicolor Precision BioDevices, runs a dedicated line for the group's diagnostic components. Production parameters and quality outcomes are held in separate systems, so yield issues are typically visible only after a batch has been completed.

    An OPC UA (Open Platform Communications Unified Architecture) bridge between production equipment and the group's quality systems gives manufacturing and quality the same view of a running batch.

    • Technicolor Precision BioDevices to Manufacture Scope Fluidics' BacterOMIC System Cartridges

  3. Building the IVDR and FDA dossier as evidence flows, not as a final compilation

    IVDR and FDA certification require clinical evidence, manufacturing validation and cybersecurity documentation compiled from R&D and manufacturing records that currently live in different places. The group's Bacteromic dossier required an International Clinical Advisory Board and additional FDA advisory work.

    A digital regulatory information layer that records evidence from the lab and the line as it is generated makes the dossier a continuous output rather than a manual collection done under deadline.

    • Scope Fluidics after Q3 2025: Secures a stronger cash position
    • Scope Fluidics expands cooperation in the FDA certification process for the UNI FAST Panel

  4. Architecting the wearable telemetry pipeline before clinical pilots

    Continuous stroke monitoring needs to move telemetry from many wearables through a clinical-grade pipeline with sub-second latency, and to do so in a way that satisfies HIPAA (US) and GDPR (EU) controls. Public materials describe the platform as 'real-time stroke prevention and diagnosis' using 'sophisticated algorithms.'

    Designing the data path, residency controls and audit trail for the cloud platform now gives the team a clear answer to the FDA and Notified Body questions about how the algorithm's output reaches a clinician in time.

    • Edocera, public company description, 2025
    • Scope Fluidics Q1-Q3 2025 results, 2025

  5. Reaching the next transaction with the data history in place

    Acquirers in medical technology do diligence on data quality, manufacturing documentation and regulatory history alongside patents. The Bio-Rad acquisition of Curiosity Diagnostics closed at around USD 130 million and is the template the group is preparing Edocera against.

    Treating data lineage, process traceability and the controlled document set as part of what is being sold means the acquirer's diligence is reading existing artefacts rather than commissioning new ones.

    • Scope Fluidics Secures USD 30 Million from Conditional Payment Settlement with Bio-Rad Laboratories
    • Historic Deal Completed, Strategic Innovation Now Advancing – Scope Fluidics Post 2024

What we'd propose

  • Digital Lab

    Shared evidence layer for the Scope Discovery pipeline

    A unified digital workspace for Scope Discovery that captures initiative data in a single, queryable form and supports initiative screening using the same evidence the team reviews by hand.

    • Initiative data capture

      Structured records from day one

      Replace ad-hoc initiative notes with structured records carrying technology area, evidence type, regulatory route and milestone status, so each initiative is comparable across the pipeline rather than only inside its own project folder.

    • Screening against past projects

      What earlier initiatives learned

      Surface prior outcomes for similar technology areas from the same evidence base, so screening is done from the group's own history rather than from the individual judgement of whoever has time to look.

    • Pipeline view for the leadership team

      One screen for 63 initiatives

      Provide an executive view of the pipeline that shows stage, evidence completeness and the next decision point for each initiative, with the underlying records one click away.

    • Each new initiative reads from the group's own evidence base instead of restarting the assessment.
    • Screening effort scales with new projects without proportionally more reviewer time.
    • Decisions on which initiative to advance are recorded against the same evidence the team reads.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    OPC UA bridge between Piaseczno production and Scope Fluidics quality

    An OPC UA information model for the Piaseczno line that connects production equipment to Scope Fluidics' quality and traceability records, so the same batch is visible to manufacturing and quality at the same time.

    • Equipment data contracts

      What each machine must publish

      Write the OPC UA information models and MQTT topic structures into procurement requirements, so interoperability is a purchase condition rather than an integration project after handover.

    • Production to quality data flow

      One batch in both views

      Stream production parameters and quality results into a shared batch record with lineage to the instrument that produced each value, so a yield question is answered from one record rather than three.

    • IEC 62443 segmentation around the new link

      OT and IT zones from day one

      Define zones, conduits and remote-access rules to IEC 62443 around the Piaseczno equipment and the Scope Fluidics side, so the link is auditable for the FDA and the Notified Body from the first pilot run.

    • Yield questions are answered from one record rather than three.
    • Interoperability is bought with the equipment rather than built after commissioning.
    • The same production record serves manufacturing, quality and regulatory inspection.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Digital regulatory information management for IVDR and FDA

    An evidence-collection layer that records clinical, manufacturing and cybersecurity data from the source systems, so the IVDR and FDA dossiers are produced continuously rather than compiled at the end.

    • Source-system evidence capture

      Records from where they are created

      Pull clinical study records, manufacturing validation results and design history items from the systems that produced them, so the dossier references the source record rather than a re-typed summary.

    • Controlled document layer

      Versioning that holds up in audit

      Hold every dossier-relevant document under version control with an audit trail that captures who approved what and when, so a Notified Body or FDA reviewer can trace each piece of evidence to its source.

    • Dual-track dossier drafting

      IVDR and FDA from one record set

      Compose the IVDR technical file and the FDA submission from the same evidence pool, with the formatting differences handled at the document layer rather than by maintaining two parallel evidence collections.

    • Dossier evidence is collected during the work rather than assembled at the end.
    • Both regulators read from the same record set, with formatting differences handled in one place.
    • Changes to source evidence are visible in the dossier without a manual rebuild.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Real-time wearable telemetry and analytics platform

    A cloud and edge architecture for the Edocera wearable that ingests telemetry from many devices with clinical-grade latency, exposes the AI output to clinicians, and records an audit trail that satisfies FDA and Notified Body review.

    • Telemetry ingestion path

      From wearable to clinical view

      Define the path from the wearable to the clinician-facing view, including the network choices, the buffering model and the freshness guarantees, so latency is a designed property of the platform rather than an emergent one.

    • Explainable model output

      What the algorithm saw, on screen

      Expose the model's inputs and confidence to the clinician at the moment of an alert, so the AI output is auditable for both the user and the regulator rather than appearing as a black-box alert.

    • GDPR and HIPAA residency controls

      Right data in the right region

      Hold EU patient data under GDPR-compliant residency and US patient data under HIPAA-aligned controls, with a single platform that records which region each record lives in.

    • Latency, residency and auditability are properties of the platform design rather than later additions.
    • Clinical users can see the model's reasoning at the moment of an alert.
    • A single platform supports EU and US pilots without a parallel deployment.

    We've done this before

    See how we do Digital CDMO
  • Agents

    AI agents for IVDR, FDA and cybersecurity documentation

    Narrow, reviewable agents that take the recurring part of regulatory and due-diligence document work: drafting IVDR and FDA submission sections from source records, checking a document against its template before review, and finding every controlled document a standards or supplier change touches. A named person approves every output.

    • Submission drafting from source records

      First drafts from system data

      Generate the first draft of an IVDR technical file section, an FDA 510(k) section or a cybersecurity documentation update directly from the underlying R&D and manufacturing records, so the author edits and judges rather than assembles.

    • Template and completeness checking

      Gaps found before review

      Check a submission draft against the relevant template and the group's own checklist, returning missing or inconsistent sections before the document enters the human review queue.

    • Change impact across the controlled document set

      Which documents a change touches

      When a standard, a supplier specification or a clinical evidence base changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one.

    • Submission drafts arrive at review already structured against the regulator's template.
    • The scope of a standards or supplier change is established by search rather than by recollection.
    • Every output is traceable to the source records it came from and signed off by a named reviewer.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Edocera Sp. z o.o.'s own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data integration 35 → 80
R&D, manufacturing and clinical evidence currently sit in separate systems across Warsaw, Piaseczno and US advisory partners. The shared evidence layer is ahead of the project rather than behind it.
Process automation 40 → 80
Pipeline screening across 63 initiatives and prototype iteration cycles are largely manual. The move to a structured discovery workspace is a precondition for adding new projects at the planned pace.
Regulatory digitalization 30 → 85
The group's IVDR dossier for Bacteromic was compiled manually with an International Clinical Advisory Board. Edocera is on the same regulatory path with the addition of FDA.
Cloud infrastructure 25 → 80
The wearable telemetry pipeline is at design stage. Sub-second latency, GDPR and HIPAA residency and an explainable AI output layer are all to be built before clinical pilots.
Manufacturing intelligence 45 → 80
The Piaseczno line is being set up with Technicolor for pilot and scale production. Predictive and digital-twin work is at the same early stage as the production line itself.
M&A readiness 40 → 85
The group's track record is the Bio-Rad acquisition of Curiosity Diagnostics at around USD 130 million. Edocera's data lineage and process documentation are being prepared against that bar.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Edocera Sp. z o.o., and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].